DrugPatentWatch Database Preview
Purdue Pharma Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for PURDUE PHARMA, and what generic alternatives to PURDUE PHARMA drugs are available?
PURDUE PHARMA has ten approved drugs.
There are eighty-one US patents protecting PURDUE PHARMA drugs.
There are nine hundred and thirty-one patent family members on PURDUE PHARMA drugs in fifty-one countries and eight supplementary protection certificates in five countries.
Summary for Purdue Pharma
| International Patents: | 931 |
| US Patents: | 81 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 10 |
| Patent Litigation for Purdue Pharma: | See patent lawsuits for Purdue Pharma |
| PTAB Cases with Purdue Pharma as patent owner: | See PTAB cases with Purdue Pharma as patent owner |
Drugs and US Patents for Purdue Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-002 | Feb 27, 2019 | RX | Yes | No | 10,292,938 | Start Trial | Y | Start Trial | |||
| Purdue Pharma Lp | HYSINGLA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 206627-004 | Nov 20, 2014 | RX | Yes | No | 8,529,948 | Start Trial | Y | Start Trial | |||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-003 | Feb 27, 2019 | RX | Yes | No | 9,974,752 | Start Trial | Y | Start Trial | |||
| Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022272-007 | Apr 5, 2010 | RX | Yes | No | 8,894,988 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Purdue Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-002 | Apr 8, 1988 | 4,366,310 | Start Trial |
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-002 | Jul 23, 2014 | 6,277,384 | Start Trial |
| Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022272-003 | Apr 5, 2010 | 6,488,963 | Start Trial |
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | 9,474,750 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PURDUE PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Tablets | 1.75 mg and 3.5 mg | ➤ Subscribe | 2012-04-10 |
| ➤ Subscribe | Transdermal System | 15 mcg/hr | ➤ Subscribe | 2013-12-16 |
| ➤ Subscribe | Extended-release Tablets | 30 mg, 40 mg, 80 mg, and 100 mg | ➤ Subscribe | 2015-05-08 |
| ➤ Subscribe | Extended-release Tablets | 30 mg and 60 mg | ➤ Subscribe | 2007-01-03 |
| ➤ Subscribe | Extended-release Tablets | 100 mg, 200 mg and 300 mg | ➤ Subscribe | 2009-06-18 |
| ➤ Subscribe | Transdermal System | 5 mcg/hr, 10 mcg/hr, and 20 mcg/hr | ➤ Subscribe | 2013-06-06 |
| ➤ Subscribe | Extended-release Tablets | 20 mg, 60 mg, and 120 mg | ➤ Subscribe | 2015-04-15 |
| ➤ Subscribe | Extended-release Tablets | 15 mg | ➤ Subscribe | 2007-02-15 |
International Patents for Purdue Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Germany | 60045695 | Start Trial |
| Argentina | 045353 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2006002883 | Start Trial |
| Hong Kong | 1087617 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Purdue Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2236132 | 92636 | Luxembourg | Start Trial | PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES |
| 2236132 | C300714 | Netherlands | Start Trial | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718 |
| 2236132 | 300714 | Netherlands | Start Trial | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718 |
| 0566709 | SPC/GB04/012 | United Kingdom | Start Trial | PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
